Prices of ASX stocks are not being updated.
The latest SPL price on Alpha Spread is from Oct 14, 2026. Financials, forecasts and intrinsic value keep updating.
Choose the stock you wish to monitor with a price target
Recently viewedPrice
↑↓ to move↵ to choose
Back to Note
Company Overview
Business Description
Sector
Health Care
Industry
Pharmaceuticals
Headquarters
AustraliaAU
Employees
50
IPO date
Sep 28, 2000
Starpharma Holdings Ltd is a biotechnology company that develops and commercializes dendrimer-based products. Its best-known products are its antiviral and antibacterial gels and coatings, including women’s health products and disinfectant or surface-treatment technologies. In simple terms, it uses its chemistry platform to make products that can block germs or carry active ingredients in a more targeted way.
The company sells these products directly in some markets and also licenses its technology to larger pharmaceutical, consumer health, and materials companies. That means it can earn money from product sales, license fees, and royalties when partners use its technology in their own products. Its main customers are healthcare providers, consumers, and corporate partners that need a specialized ingredient or product platform rather than a full drug discovery engine.
What makes Starpharma different is that it sits between a drug developer and a technology supplier. Instead of making a broad range of medicines, it focuses on a proprietary molecular platform that can be adapted for medical, consumer, and industrial uses. This gives the business a mix of direct product revenue and partner-driven revenue, which is common in specialty biotech but less like a traditional drug maker.
This part of the business develops dendrimer-based medicines and medical products, including treatments and prevention products for infections. Starpharma also works with partners to move these products through testing a...
Customers and revenue model
Consumer health products
This part sells Starpharma-branded products designed for everyday infection prevention, such as personal care and over-the-counter health products that use the company’s technology.
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.